52,348 ACADIA Pharmaceuticals Inc. $ACAD Shares Bought by Alps Advisors Inc.

Key Points

• Alps Advisors increased its ACADIA stake by 26.6% in the third quarter, buying 52,348 shares to hold 249,397 shares valued at about $5.0 million.
• Institutional investors and hedge funds own 96.71% of ACADIA shares; several firms reported new positions or increased holdings.
• ACADIA’s third-quarter revenue rose 22.8% year over year to $342.3 million, beating estimates, while earnings of $0.31 per share also exceeded forecasts.

Alps Advisors Inc. raised its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 26.6% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 249,397 shares of the biopharmaceutical company's stock after purchasing an additional 52,348 shares during the period. Alps Advisors Inc. owned 0.14% of ACADIA Pharmaceuticals worth $5,025,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. BlackRock Inc. bought a new stake in ACADIA Pharmaceuticals in the second quarter valued at about $569,634,000. Palo Alto Investors LP bought a new position in ACADIA Pharmaceuticals during the second quarter worth $72,461,629. Bank of America Corp DE bought a new position in ACADIA Pharmaceuticals during the second quarter worth $32,900,000. First Trust Advisors LP boosted its holdings in ACADIA Pharmaceuticals by 47.3% in the first quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company's stock worth $74,435,000 after purchasing an additional 1,073,834 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in ACADIA Pharmaceuticals in the second quarter worth $19,244,000. Institutional investors and hedge funds own 96.71% of the company's stock.

More ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: RBC raised its price target to $41 from $31 and maintained an Outperform rating, citing continued momentum for Daybue. RBC price-target update RBC Daybue commentary
• Positive Sentiment: Canaccord Genuity raised its target to $38 from $36 and reiterated a Buy rating, adding to the favorable analyst outlook. Canaccord analyst recommendations
• Positive Sentiment: ACADIA reported Q3 revenue of $342.3 million, above the roughly $332.6 million consensus, and earnings of $0.31 per share, ahead of estimates around $0.19–$0.20. Revenue increased 22.8% year over year, reinforcing the company’s growth story. Q3 earnings results
• Neutral Sentiment: The company revised its 2026 earnings guidance, but the provided report headline does not disclose the direction or magnitude of the change. Investors will need the detailed guidance to assess its implications. 2026 earnings guidance update

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ACAD shares. Stifel Nicolaus lifted their price target on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a "hold" rating in a report on Tuesday, July 21st. UBS Group lowered shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $49.00 to $23.00 in a research note on Tuesday, October 13th. Citizens Jmp dropped their price objective on shares of ACADIA Pharmaceuticals from $36.00 to $33.00 and set a "market outperform" rating on the stock in a research note on Friday, September 25th. Morgan Stanley raised their target price on shares of ACADIA Pharmaceuticals from $27.00 to $28.00 and gave the stock an "equal weight" rating in a report on Tuesday, August 25th. Finally, Canaccord Genuity Group lifted their target price on ACADIA Pharmaceuticals from $36.00 to $38.00 and gave the company a "buy" rating in a research note on Friday. Thirteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.55.

Insider Activity at ACADIA Pharmaceuticals

In other news, EVP Mark Schneyer sold 3,321 shares of the company's stock in a transaction on Friday, October 30th. The stock was sold at an average price of $20.88, for a total value of $69,342.48. Following the completion of the sale, the executive vice president owned 71,322 shares in the company, valued at $1,489,203.36. This represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 26.20% of the company's stock.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD opened at $21.23 on Monday. ACADIA Pharmaceuticals Inc. has a one year low of $18.39 and a one year high of $30.96. The stock's fifty day moving average is $22.86 and its 200-day moving average is $23.59. The firm has a market capitalization of $3.66 billion, a price-to-earnings ratio of 10.06 and a beta of 0.87.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.11. The firm had revenue of $342.30 million during the quarter, compared to the consensus estimate of $332.58 million. ACADIA Pharmaceuticals had a return on equity of 8.90% and a net margin of 30.13%. The firm's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.42 earnings per share. Analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.74 EPS for the current fiscal year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations.

Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.